Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
A next-generation Novo Nordisk metabolic disorder drug led to statistically significant weight loss in a pivotal test in participants with obesity and type 2 diabetes, results it says support ...
Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback